Kaveri Pohlman
Stock Analyst at Clear Street
(2.70)
# 4,006
Out of 5,182 analysts
34
Total ratings
40.62%
Success rate
0.16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTGX Protagonist Therapeutics | Maintains: Buy | $104 → $116 | $98.51 | +17.75% | 1 | Apr 7, 2026 | |
| EVMN Evommune | Initiates: Buy | $53 | $25.00 | +112.00% | 1 | Mar 18, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $45 → $70 | $16.85 | +315.43% | 1 | Mar 11, 2026 | |
| ERAS Erasca | Maintains: Buy | $11 → $20 | $19.15 | +4.44% | 1 | Mar 6, 2026 | |
| JANX Janux Therapeutics | Downgrades: Hold | $32 → $12 | $15.23 | -21.21% | 3 | Jan 20, 2026 | |
| PALI Palisade Bio | Initiates: Buy | $12 | $1.96 | +512.24% | 1 | Dec 30, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $61 → $99 | $45.33 | +118.40% | 1 | Dec 9, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Buy | $200 | $128.64 | +55.47% | 1 | Dec 5, 2025 | |
| JBIO Jade Biosciences | Initiates: Buy | $25 | $26.64 | -6.16% | 1 | Nov 25, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Buy | $11 → $21 | $14.27 | +47.16% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.41 | +232.72% | 1 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $8.12 | +257.14% | 1 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 | $76.39 | -39.78% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $30.33 | +5.51% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.05 | - | 4 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $46 → $47 | $26.64 | +76.43% | 3 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $30 | $13.25 | +126.42% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $38 | $13.10 | +190.08% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $5 | $4.56 | +9.65% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.76 | +354.55% | 1 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $44.65 | -39.53% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $24.95 | +180.56% | 1 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $7.72 | +55.44% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $4.29 | +86.48% | 2 | Jul 7, 2022 |
Protagonist Therapeutics
Apr 7, 2026
Maintains: Buy
Price Target: $104 → $116
Current: $98.51
Upside: +17.75%
Evommune
Mar 18, 2026
Initiates: Buy
Price Target: $53
Current: $25.00
Upside: +112.00%
MoonLake Immunotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $45 → $70
Current: $16.85
Upside: +315.43%
Erasca
Mar 6, 2026
Maintains: Buy
Price Target: $11 → $20
Current: $19.15
Upside: +4.44%
Janux Therapeutics
Jan 20, 2026
Downgrades: Hold
Price Target: $32 → $12
Current: $15.23
Upside: -21.21%
Palisade Bio
Dec 30, 2025
Initiates: Buy
Price Target: $12
Current: $1.96
Upside: +512.24%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $61 → $99
Current: $45.33
Upside: +118.40%
Palvella Therapeutics
Dec 5, 2025
Initiates: Buy
Price Target: $200
Current: $128.64
Upside: +55.47%
Jade Biosciences
Nov 25, 2025
Initiates: Buy
Price Target: $25
Current: $26.64
Upside: -6.16%
Trevi Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $11 → $21
Current: $14.27
Upside: +47.16%
Nov 13, 2025
Initiates: Buy
Price Target: $18
Current: $5.41
Upside: +232.72%
Oct 22, 2025
Initiates: Buy
Price Target: $29
Current: $8.12
Upside: +257.14%
Sep 17, 2025
Maintains: Buy
Price Target: $46
Current: $76.39
Upside: -39.78%
Jun 25, 2025
Initiates: Buy
Price Target: $32
Current: $30.33
Upside: +5.51%
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.05
Upside: -
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $26.64
Upside: +76.43%
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $13.25
Upside: +126.42%
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $13.10
Upside: +190.08%
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $4.56
Upside: +9.65%
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $1.76
Upside: +354.55%
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $44.65
Upside: -39.53%
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $24.95
Upside: +180.56%
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $7.72
Upside: +55.44%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $4.29
Upside: +86.48%